Legend is developing cell therapies that aim to help strengthen patients’ immune systems to fight disease.

We explore several innovative and evolving technologies to treat blood and solid cancers: autologous chimeric antigen receptor T-cell therapy (CAR-T); and allogeneic CAR-T, natural killer (NK) cells and gamma-delta (γδ) T cells. As a global team, we are building a fully integrated cell therapy platform and advancing multiple agents in the process.

Our approach

Today we have multiple therapeutic candidates in development built on our R&D team's three core strengths:

Deep expertise

We have in-house antibody screening and engineering capabilities

Multiple allogeneic platforms

Diverse allogeneic platforms, including non-gene editing universal CAR-T and NK, which may offer benefits in safety and CMC production

Attention to detail

Multiple armoring strategies to overcome challenges in treating solid tumors


You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.